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ABSTRACT Bronchiectasis has been a largely overlooked disease area in respiratory medicine. This is
reflected by a shortage of large-scale studies and lack of approved therapies, in turn leading to a variation
of treatment across centres. BronchUK (Bronchiectasis Observational Cohort and Biobank UK) is a
multicentre, prospective, observational cohort study working collaboratively with the European Multicentre
Bronchiectasis Audit and Research Collaboration project. The inclusion criteria for patients entering the
study are a clinical history consistent with bronchiectasis and computed tomography demonstrating
bronchiectasis. Main exclusion criteria are 1) patients unable to provide informed consent,
2) bronchiectasis due to known cystic fibrosis or where bronchiectasis is not the main or co-dominant
respiratory disease, 3) age <18 years, and 4) prior lung transplantation for bronchiectasis. The study is
aligned to standard UK National Health Service (NHS) practice with an aim to recruit a minimum of
1500 patients from across at least nine secondary care centres. Patient data collected at baseline includes
demographics, aetiology testing, comorbidities, lung function, radiology, treatments, microbiology and
quality of life. Patients are followed up annually for a maximum of 5 years and, where able, blood and/or
sputa samples are collected and stored in a central biobank. BronchUK aims to collect robust longitudinal
data that can be used for analysis into current NHS practice and patient outcomes, and to become an
integral resource to better inform future interventional studies in bronchiectasis.
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Bronchiectasis is now being recognised for its increasing importance to people affected by the condition,
and has been neglected in respiratory medicine [1, 2]. In contrast to conditions such as asthma and
COPD, bronchiectasis has previously been viewed as an ‘orphan disease’ [3, 4]. Recent data consistently
show an increasing prevalence of the condition across European and US healthcare systems [5–7],
emphasising the need for better resourced research in this area.
This need is reflected by a lack of large-scale cohorts and the recruitment of well-characterised patients
into intervention studies. There are few, if any, drug therapies specifically licensed for bronchiectasis
available across multiple countries [8–10] and current guidelines remain mostly reliant on studies with
low-grade evidence [11, 12]. Naturally, this leads to variations in care.
A recent upsurge in interest has revitalised the field and the European roadmap project for bronchiectasis
has helpfully delineated the priorities in bronchiectasis [13]. However, major questions remain unanswered
that can be facilitated by better epidemiological data, better understanding of the natural history of the
disease and risk factors for adverse outcomes such as exacerbations, hospitalisations and mortality [13].
The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) project has helped
create a network of bronchiectasis centres across Europe that are recruiting patients into a multinational
study [14–16]. In parallel to this, the UK bronchiectasis community recognised a need to understand
healthcare outcomes and variation in practice across the UK. The Bronchiectasis Observational Cohort and
Biobank UK (BronchUK) is a project arising from a Medical Research Council (MRC)-funded partnership
that consists of a consortium and is also the name of the associated database. The UK bronchiectasis
consortium is an expanding group based around the recruiting centres plus affiliated scientific experts in
other fields (e.g. microbiology and health economics). BronchUK is envisaged as a focal point for the UK
bronchiectasis community with a number of workshops led by BronchUK members but open to the wider
community. BronchUK complements EMBARC, with significant elements of the projects overlapping,
including the database design and platform allowing comparisons across the wider EMBARC dataset.
In addition, BronchUK has a biobank and regulatory approval to link individual patient data to national
healthcare data (see table 1, shared and unique elements between EMBARC and BronchUK). Existing and
prospective study designs and recruitment will be enhanced by cohorts of well-characterised patients,
particularly where patients have given consent to be contacted for future research studies. The UK offers
an important test bed for many aspects of bronchiectasis care with free healthcare at the point of access
and established bronchiectasis guidelines, published by the British Thoracic Society (BTS) in 2010 and
recently updated [1], with subsequent national audits [17, 18]. The potential to utilise UK data systems for
healthcare usage and outcomes enables exploratory analyses between the treatment regimens and patient
outcomes, which will in turn better inform future intervention studies.
Study objectives
The objectives of the study are: to develop a multicentre bronchiectasis registry incorporating baseline data
collection with annual follow-up data for at least 5 years; to facilitate the creation of a biobank in
bronchiectasis to underpin future mechanistic studies; to describe the treatment patterns across the UK,
phenotypic data, comorbidities and healthcare use; to facilitate multinational cooperation, especially with
EMBARC, within academia and with industry to develop new discoveries; to develop key partnerships
with experts not currently working in bronchiectasis to optimally use the datasets.
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London, London, UK. 8University Hospital Southampton NHS Foundation Trust, Southampton, UK. 9College of
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NHS Foundation Trust, Birmingham, UK. 11UCL Respiratory, University College London, London, UK. 12Cardiff
and Vale University Health Board, Cardiff, UK. 13Altnagelvin Area Hospital, Western Health and Social Care
Trust, Londonderry, UK. 14North Tyneside General Hospital, Northumbria Healthcare NHS Foundation Trust,
North Shields, UK. 15University Hospitals of Morecambe Bay NHS Foundation Trust, Morecambe, UK.
16Liverpool University Hospitals, Liverpool, UK. 17University of Liverpool, Liverpool, UK. 18London School of
Economics, London, UK. 19The University of Manchester, Manchester, UK.
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Study design
The registry is a multicentre, prospective, observational cohort study enrolling consecutive adult patients
with radiologically confirmed bronchiectasis across the UK. The study is noninterventional and recruiting
from secondary care centres (see table 2, full list of participating centres). BronchUK runs in parallel with
the EMBARC trial protocol as published and is acknowledged herein, where appropriate repetition is
included.
The study collects baseline data and delineates routine practice across participating secondary care centres
aligned to prevailing national and international guidelines on aetiological testing and monitoring of
bronchiectasis. Patients giving informed consent to participate have baseline data collected and annual
review data recorded via routine hospital visits for up to 5 years. These include basic demographics;
reported comorbidities; results from aetiological testing; pulmonary function tests; recent sputum
microbiology; health-related quality of life (HRQoL); symptoms (including MRC dyspnoea); radiological
data; treatment and physiotherapy regimens and healthcare usage/exacerbation rates (figure 1).
BronchUK received central ethical approval from the National Research Ethics Service Committee North
East – Newcastle and North Tyneside 1, ( July 17, 2015, ref. 15/NE/0172) and is led by Newcastle
University, UK, with National Health Service (NHS) sponsorship provided by the Newcastle upon Tyne
Hospitals NHS Foundation Trust. The study website is located at www.bronch.ac.uk. The registry was
developed in alignment with EMBARC with additional features of linking patients’ routine study data with
national healthcare databases, including the UK Office of National Statistics (ONS) dataset. Furthermore,
recruiting centres with access to appropriate facilities can also biobank sputum, serum and plasma.
TABLE 1 EMBARC and BronchUK shared and unique elements







Quality of life measures
Mortality and exacerbation
rates
Linked healthcare data to confirm healthcare use (and compare regimens
within one healthcare system)
Psychological measurements (anxiety and depression scores)
Linked to national mortality data sets
Potential to link with NHS digital and or other NHS number linked projects
(PHOS-COVID)
Samples stored in biobank
EMBARC: European Multicentre Bronchiectasis Audit and Research Collaboration; BronchUK:
Bronchiectasis Observational Cohort and Biobank UK; CT: computed tomography; NHS: National Health
Service.
TABLE 2 Full list of participating NHS centres
Freeman Hospital (Newcastle upon Tyne Hospital NHS FT)
University College Hospital (University College London Hospitals NHS FT)
Royal Infirmary of Edinburgh (NHS Lothian)
The Wellcome Trust-Wolfson NI CRF (Belfast Health and Social Care Trust)
Royal Papworth Hospital (Royal Papworth Hospital NHS FT)
University Hospital Llandough (Cardiff and Vale University Health Board)
Queen Elizabeth Hospital (University Hospitals Birmingham NHS FT)
Royal Brompton Hospital (Royal Brompton and Harefield NHS FT)
Southampton General Hospital (University Hospital Southampton NHS FT)
Altnagelvin Area Hospital (Western Health and Social Care Trust)
Royal Free Hospital (Royal Free London NHS FT)
North Tyneside General Hospital (Northumbria Healthcare NHS FT)
Royal Lancaster Infirmary (University Hospitals of Morecambe Bay NHS FT)
Aintree University Hospital (Liverpool University Hospitals NHS FT)
Ninewells Hospital (NHS Tayside)
NHS: National Health Service; BronchUK: Bronchiectasis Observational Cohort and Biobank UK; FT:
Foundation Trust.
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Participants
Participants are patients with a primary diagnosis of bronchiectasis that meet the following inclusion and
exclusion criteria. The inclusion criteria of this study are: adults with a clinical history consistent with
bronchiectasis (cough, chronic sputum production and/or recurrent respiratory infections); and historical
computed tomography (CT) of chest demonstrating bronchiectasis (bronchial dilatation) affecting one or
more lobes.
The exclusion criteria are: patients who are unable or unwilling to provide informed consent;
bronchiectasis due to known cystic fibrosis or bronchiectasis is not the main or co-dominant respiratory
disease; prior lung transplantation for bronchiectasis; and patients already enrolled into EMBARC.
Identification and recruitment
Patients are identified and recruited from secondary care outpatient clinics in either general respiratory or
specialist hospital clinics. It should be noted that participants entering BronchUK cannot be
simultaneously entered into EMBARC. This is to avoid inadvertent double counting of the same patient as
two individual patients in the larger EMBARC dataset.
Follow-up
Patient data are collected on an annual basis (within a 6-month variance) aligned to routine clinical
attendance for up to 5 years, unless a patient is clinically discharged or withdraws from the study.
HRQoL
The registry uses both the ‘Quality of Life – Bronchiectasis’ questionnaire version 3.1 [19] and the
St George’s Respiratory Questionnaire (SGRQ) [20]. An automatic calculator tool is incorporated into the
registry platform to aid calculation. The former reflects the use of this in EMBARC as it is the only
disease-specific HRQoL tool that has been specifically developed and validated for bronchiectasis. We have
included the SGRQ as this has prior validation in bronchiectasis and allows comparison to other datasets.
We also included the Hospital Anxiety and Depression Scales to define the extent of psychological
comorbidity in bronchiectasis.
Screening
Patient attending secondary care meets inclusion criteria:
1) Clinical and radiological diagnosis of bronchiectasis 
  with documented evidence of bronchiectasis on CT scanning
2) Any suspected aetiological cause of bronchiectasis 
  (except cystic fibrosis)
Exclusion criteria
1) Cognitive impairment
2) Terminal illness not related to bronchiectasis
3) Aged <18 years
4) Bronchiectasis is not main or codominant  
  respiratory disease
5) Lung transplantation for previous bronchiectasis
6) Inability to attend yearly clinical follow-up
7) Unable to provide informed consent
Biobanking
If patient agrees to blood and sputa/genetic 
samples, these will be stored initially at site before 
being shipped to central Biobank in a batch
Samples are collected ideally at baseline and year 3
Informed consent
Patient gives informed consent with permission to link to NHS 
number, collect samples, and for data to be used in future 
studies. Optional consent included to score samples for ≤10 
years and to contacted about future research studies.
Baseline
Data collection: demographics, aetiology testing, 
comorbidities,  lung function, radiology, treatments, 
microbiology and quality of life
Annual follow-up for up to 5 years
Repeat data fields from baseline and update patient status or 
record reason for discontinuing (i.e. clinical discharge, patient 
withdrawal, or death)
FIGURE 1 Study flow chart. CT: computed tomography.
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Aetiology
The aetiology of bronchiectasis is determined by the physician caring for the patient. However, extensive
data are collected on the aetiological testing performed. Based on the testing recommended by consensus
guidelines, the underlying basis for an aetiological diagnosis is collected and can be validated [21].
Exacerbations
We followed the EMBARC proposal to use a pragmatic definition of an exacerbation, allowing
self-managed exacerbations to be included [14]. Severe exacerbations are defined as per BTS criteria as an
exacerbation requiring hospital admission (or hospital-at-home management [1]). Hospital attendances
such as emergency room visits that do not result in hospital admission are also recorded.
Sputum colour
Sputum colour is evaluated using a validated photographic sputum colour chart that rates colour from 1
(mucoid) to 4 (highly purulent) [22].
Lung function
Lung function is recorded as noted in the EMBARC protocol with height, weight and post-bronchodilator
spirometry values [23] consistent with American Thoracic Society (ATS)/European Respiratory Society
(ERS) guidelines as per EMBARC [14].
Severity of disease
The variables required to calculate the Bronchiectasis Severity Index (BSI) are recorded [24], such as
history of hospitalisations, MRC dyspnoea score and radiological extent of disease. Like EMBARC, the
database platform automatically calculates BSI scores [14, 24].
Smoking status
Current and past smoking status was determined, including pack-years smoked.
Comorbidity
We record other respiratory (e.g. asthma, COPD) and nonrespiratory comorbidity.
Microbiology
Microbiology data arising from any sample (sputum, bronchoalveolar lavage, induced sputum) collected in
either stable state or at exacerbation is recorded. To align data with EMBARC, we adopted the definition
of colonisation as two positive samples at least 3 months apart when clinically stable. We also collect any
routinely available antibiotic susceptibility test results. Again, in alignment with EMBARC, reflecting the
clinical importance of Pseudomonas aeruginosa in driving exacerbations and mortality, the database will
collect specific data on P. aeruginosa, including any historical isolation of P. aeruginosa. Furthermore,
wherever recorded clinically, we also enter mucoid versus nonmucoid status for Pseudomonas data. There
is a section for entry of anti-Pseudomonas therapy, including nebulised antibiotics and any eradication
treatments used.
Radiology
Reflecting the simple nature of the Reiff score [25] and the adoption of this into the EMBARC registry, we
are asking recruiting centres to use this system. Historical CT scans are recorded at baseline and any scan
undertaken during the study for clinical reasons are entered in the subsequent annual review form. There
is the ability to look at longitudinal changes in CT but only where scans were undertaken for clinical
reasons as per routine hospital care. We have not sought funding for over-reading of CT scans, in part, as
it is highly complex and expensive to coordinate across multiple centres.
Treatments
Details are recorded on treatment, including all oral and inhaled therapies and maintenance antibiotics
(systemic or pulmonary targeted, mucoactive drugs and anti-inflammatories). Comprehensive data on
physiotherapy practise are also recorded, along with vaccination status. Treatment options are regularly
updated as new therapies complete randomised trials and become available during the study.
Quality control
The database has been adapted from the EMBARC platform allowing a well-established platform with
integral quality control to be applied. As previously, the database incorporates automated logic checks to
alert users when data entered are outside expected range and to prevent incorrect values being entered.
Each case entered into the registry is manually verified by a member of the central study team and data
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queries, including any missing values, are resolved with the study site. We have followed the source data
verification and random audit at study sites employed in EMBARC to ensure quality. Furthermore, we
have included on-site monitoring and assessment of data entry in a subset of patients where necessary.
Source data verification and random audit is also conducted across study sites.
Governance and unique identifiers
Reflecting the study’s aim to characterise disease burden and healthcare use, we gained overarching
national regulatory approval and individual patient permission during consent to link patient data to a
unique identifier. This identifier allows patients to be cross-referenced with UK healthcare data
(digital.nhs.uk) and the ONS (www.ons.gov.uk) giving us both healthcare use and mortality data. This
ability to identify patients results in a data-handling protocol limiting all data to a ‘Safe Haven’. We have
worked with the Health Informatics Centre (HIC) based at the Farr institute, University of Dundee, to
provide a process that prevents identifiable data to be exported from Safe Haven.
Biobank sampling
Samples being biobanked depend on the capability of each individual centre. We are biobanking whole
blood suitable for DNA extraction and genotyping studies, as well as serum and plasma suitable for
biomarker studies. Sputum is stored for future microbiome analysis and in selected centres sputum sol is
also be prepared suitable for inflammatory marker analyses. These samples should allow endo-typing of
bronchiectasis and correlation with genomic data from both the host and microbiome in future studies.
The biobanking follows a standardised operating procedure (SOP), though not all sites are able to provide
all samples in all patients. The quality control for the samples is based on audits of the SOP worksheets.
Patients can still be recruited into the study even if they are unable to provide samples.
Sample size
We chose a pragmatic sample size of 1500 patients, allowing for rare disease aetiologies to be captured.
Our aim was to have at least nine centres recruiting to allow for a geographic spread across the UK. We
have broadened this to include up to 15 centres with further centres welcomed.
Governance, oversight and data sharing
The study is conducted in accordance with the principles of Good Clinical Practice. We have obtained
approvals from the national Health Research Authority and each partner site requires separate institutional
approval.
The registry is held securely in the University of Dundee HIC parallel to the EMBARC registry. Our data
are shared with EMBARC to allow a bigger European dataset.
Access to the data is first considered via an approvals process and access committee. The data are retained
within the Safe Haven model (www.scot-ship-toolkit.org.uk/information-page/ship-safe-havens) and can be
accessed either through a closed virtual desktop that allows secure access and data analysis but prevents
copying or downloading of data, or data can be extracted and processed into summary format by the
study team and then provided to the requesting researcher with no identifiers. Both models ensure
complete data security. Active investigators and other stakeholders have unrestricted access to their own
NHS site data. As per EMBARC, the database and governance processes surrounding data management
and access are fully compliant with the UK Data Protection Act 1998 and the Data Protection Directive
95/46/EC of the European Parliament and of the Council (1995).
Access to the biobank also requires approvals from the biobank access committee of BronchUK. Priority is
given to those with formed projects and appropriate ethical approval and funding in place to conduct the
study.
The BronchUK study group follows the International Committee of Medical Journal Editors
recommendations regarding authorship. The results of the study are disseminated in the form of annual
reports, conference abstracts and peer-reviewed publications.
Discussion
Bronchiectasis research is helping to tackle major gaps in our understanding of the disease and moving us
towards completion of the roadmap tasks [13]. Reflecting the heterogeneity within bronchiectasis, the
larger European registry is well placed to define the importance of certain rare aetiologies and provide a
good view of variation across countries.
These large registries are needed as rare diseases or aetiologies are unlikely to be well represented in single
centre studies. Prior multicentre studies have helped show the importance of bronchiectasis and
https://doi.org/10.1183/23120541.00775-2020 6
BRONCHUK | A. DE SOYZA ET AL.
rheumatoid arthritis overlap (BROS) as having possible adverse prognostic effects [26]. One notable aspect
of this study was the variation in rates of BROS between centres. This may depict referral patterns, local
healthcare systems or genuine differences in the rates of BROS between countries. The aim of BronchUK
is therefore to study variation within a country where access to healthcare is expected to be similar and
where we can track disease outcomes using national datasets of healthcare use [27].
Strengths of the project include using a platform compatible with EMBARC datasets and the rigorous
quality control mechanisms already successfully applied within EMBARC. Consistency of data collection
methods and alignment of databases will allow comparison across international registries such as
EMBARC, the Indian Bronchiectasis Registry, the Australian Bronchiectasis Registry [28] and KMBARC
registry [29]. These data enable a more global comparison of disease characteristics and management and
this approach has already helpfully highlighted important differences between European and Indian
patients [30].
A further strength is the biobanking of samples for future biomarker and/or genetic analysis. This allows
mechanistic studies to be conducted.
Certain limitations need to be acknowledged. The study is recruiting from a number of centres across the
UK with a large sample size. However, despite this, it is possible we will not capture the full experiences of
patients across the UK. Importantly, patients that are being recruited into EMBARC from UK sites cannot
be simultaneously recruited into BronchUK. Keeping the projects separate at recruitment allows centres
that cannot biobank contribute to EMBARC, and centres that can biobank, contribute to BronchUK. This
avoids double counting of the same patient when BronchUK datasets are shared/imported into the larger
EMBARC dataset. The ability to pool EMBARC-UK data and BronchUK data will, however, give us a
powerful tool to capture not only a broader national view of bronchiectasis care in the UK but also how
variation across a single healthcare system might inform better care.
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